The present disclosure is generally related to methods and apparatus to insert and remove implantable devices. Although specific reference is made to placement in the eye, embodiments as described herein can be used with many implantable devices in locations away from the eye, such as orthopedic, intraluminal and transdermal locations.
Implantable devices can be used to provide a therapeutic agent to one or more locations of a patient. The implantable device may have a reservoir of therapeutic agent, and a structure to retain the implantable device at a desired location of the patient. The implantable device may have a chamber for storing the therapeutic agent, and the agent can be released into the patient to provide a therapeutic benefit. After an amount of time, the amount of fluid released can be less than ideal, and the fluid of the implantable device may be replaced, refilled, or exchanged to provide additional amounts of therapeutic agent to extend the therapy.
The prior methods and apparatus to place an implantable device in the body can be less than ideal in at least some instances. For example, the amount of therapeutic fluid placed in an implanted therapeutic device with injection can be less than ideal in at least some instances. At least some of the prior devices implanted in the eye can be small to decrease interference with vision, and the refill port of such devices can be difficult to fill in at least some instances. The eye can move, and alignment and placement of the implantable device in the eye can be more difficult than would be ideal in at least some instances.
In light of the above, it would be desirable to provide improved treatments for the eye and improved methods and apparatus to place implantable devices in the eye and to place therapeutic fluids in the implantable devices. Ideally, these treatments, methods and apparatus would decrease at least some of the deficiencies of the prior methods and apparatus, and would provide improved placement and removal of devices implanted within the eye.
Embodiments of the present disclosure provide improved methods and apparatus to insert and remove an implantable device to treat a patient. In many embodiments, the methods and apparatus can provide injection of a therapeutic agent into an implantable device prior to insertion. The implantable device can be manufactured and provided to a clinic without a therapeutic agent, such that the therapeutic agent can be placed in the implantable device in the clinic prior to insertion.
In a first aspect, described herein is an apparatus to insert an implantable therapeutic device into a patient. The apparatus includes a proximal handle, and a distal placement portion coupled to the proximal handle and configured to hold the implantable therapeutic device. The distal placement portion includes a first side having a first engagement structure at a distal end of the first side, the first engagement structure configured to surround at least a first portion of a proximal end region of the implantable therapeutic device. The distal placement portion includes a second, opposite side having a second engagement structure at a distal end of the second side, the second engagement structure configured to surround at least a second, opposite portion of the proximal end region of the implantable therapeutic device.
The apparatus can further include the implantable therapeutic device. The implantable therapeutic device can include a retention structure at the proximal end region having a narrow portion, a shoulder and a proximal extension. Each of the first and second engagement structures can include a protrusion having a surface contour shaped and sized to engage a portion of the retention structure. Each of the protrusions can be configured to extend into the narrow portion. The protrusions can extend into the narrow portion, a proximal surface of each protrusion can engage a distal surface of the proximal extension and a distal surface of each protrusion can engage the shoulder.
The distal placement portion can further include a recess through which a proximal surface of the proximal extension is accessible. The distal placement portion can further include a guide having at least one guide surface configured to support and maintain alignment of a needle extending at an angle oblique to a longitudinal axis of the implantable device prior to penetration of the implantable device by the needle. The needle can include a connector and wherein the at least one guide surface has a shape complimentary to the connector to receive the connector and maintain alignment of the needle relative to the implantable device. The proximal handle can include first and second opposing handles extending on opposite sides of a longitudinal axis. The first opposing handle can be coupled to a proximal end of the first side and the second opposing handle can be coupled to a proximal end of the second side. The first and second opposing handles can be configured to urge the first side and the second side toward each other to engage the implantable device when the first and second opposing handles move away from the axis and to urge the first side and the second side away from each other to release the implantable device when the first and second opposing handles move toward the axis. The first and second opposing handles can be configured to urge the first side and the second side toward each other to engage the implantable device when the first and second opposing handles move toward the axis and to urge the first side and the second side away from each other to release the implantable device when the first and second opposing handles move away from the axis.
In an interrelated aspect, disclosed herein is a method of treating a patient including holding with an insertion apparatus an implantable device having an axis and a penetrable barrier, such that the axis of the implantable device and an axis of the insertion apparatus are concentric. The method includes advancing a needle through the penetrable barrier at an angle oblique to the concentric axes. The method includes injecting a therapeutic fluid through the needle advanced through the penetrable barrier and into a reservoir chamber of the implantable device. The method includes implanting the implantable device into an incision in a tissue of the patient.
The axis of the implantable device and the axis of the insertion apparatus can be concentric when the therapeutic fluid is injected into the reservoir chamber of the implantable device.
In an interrelated aspect disclosed herein is a kit to treat a patient including an insertion apparatus of any of those described herein, an implantable therapeutic device, and packaging to contain the insertion apparatus and the implantable therapeutic device.
Additional aspects are recited in the claims below, and can provide additional summary in accordance with embodiments as described herein. It is contemplated that the embodiments as described herein and recited in the claims may be combined in many ways, and any one or more of the elements recited in the claims can be combined together in accordance with embodiments and teachings as described herein.
FIG. 2C1 shows a side view of the short axis of the narrow neck portion of the therapeutic device as in
FIG. 2C2 shows a side view of the long axis of the narrow neck portion of the therapeutic device as in
Embodiments as described herein can be combined in many ways to treat one or more diseases of a patient such as a disease of the eye. The embodiments as described herein are well suited to treat patients with a therapeutic agent for an extended time, such as may be provided with an implantable device. Although specific reference is made to ophthalmic treatment of the eye, the methods and apparatus to place and remove an implantable device can be used with many implantable devices and treatments of one or more of many diseases, such as systemic medication to treat systemic disease, orthopedic treatment to treat orthopedic disorders, or dental treatment, for example. The insertion and removal apparatus and methods as described herein are well suited for use with many drug delivery devices, such as refillable diffusion based devices, and can be exceptionally well suited for diffusion devices having a porous drug release structure configured for extended release in which the porous structure inhibits flow of fluid during exchange. The insertion and removal apparatus and methods as describe herein are well suited for diagnoses and treatment of the eye, for example with diagnosis and treatment of the eye based on the implantable device fluid received with the exchange apparatus with the fluid is injected. The methods and apparatus as described herein are well suited for combination with implantable devices and injector apparatus as described in U.S. patent application Ser. No. 12/696,678, filed on Jan. 29, 2010, entitled “Posterior Segment Drug Delivery”, Publication No. 2010/0255061; and U.S. PCT Pat. App. No. PCT/US2011/046812, filed Aug. 5, 2011, entitled “Injector Apparatus and Method for Drug Delivery”, the entire disclosures of which are incorporated herein by reference.
As used herein like numerals and/or letters denote like elements in the drawings and text as will be apparent to a person of ordinary skill in the art.
While the implant can be positioned in the eye in many ways, work in relation to embodiments suggests that placement in the pars plana region can release therapeutic agent into the vitreous to treat the retina, for example therapeutic agent including an active ingredient composed of large molecules.
Therapeutic agents 110 suitable for use with device 100 include one or more of many therapeutic agents, for example as listed in Table 1A, herein below. The therapeutic agent 110 of device 100 can include one or more of an active ingredient of the therapeutic agent, a formulation of the therapeutic agent, a commercially available formulation of the therapeutic agent, a physician prepared formulation of therapeutic agent, a pharmacist prepared formulation of the therapeutic agent, or a commercially available formulation of therapeutic agent having an excipient. The therapeutic agent may be referred to with generic name or a trade name, for example as shown in Table 1A.
The therapeutic device 100 can be implanted in the eye to treat the eye for as long as is helpful and beneficial to the patient. For example the device can be implanted for at least about 5 years, such as permanently for the life of the patient. Alternatively or in combination, the device can be removed when no longer helpful or beneficial for treatment of the patient.
In many embodiments, the retention structure 120 includes a shoulder 120S extending from the narrow portion 120N to the wall of the reservoir chamber 140, which can include a rigid or expandable annular wall. The shoulder portion 120S can extend from the narrow portion so as to engage the sclera opposite extension 122 and hold the device 100 in the pars plana region. The shoulder 120S of retention structure 120 can include a first shoulder 120S1 on a first side of the retention structure and a second shoulder 120S2 on a second side of the retention structure with axis 120N1 extending therebetween (as shown in 1C-5). Alternatively, the retention structure 120 can include a rotationally symmetric narrow portion 120N having a first side and a second side to fit a dilated incision of the eye, for example, and shoulder 120S can include a rotationally symmetric shoulder extending from the narrow portion 120N to engage a lower portion of the sclera.
The elongate cross section 120NE, shown in
The porous structure 150 can be located on a distal end portion of the therapeutic device, and the retention structure 120 can be located on a proximal portion of therapeutic device 100, as shown in
The reservoir 130 can be configured in many ways, and can include a rigid walled reservoir, for example, or an expandable reservoir. The barrier 160 may define a size of reservoir 130. The barrier 160 and reservoir 130 may each include a circular, an elliptical, oval or other cross-sectional size, for example.
The retention structure includes narrow portion 120N having short distance 120NS and long distance 120NL so as to fit in an elongate incision along the pars plana of the eye. The retention structure includes extension 122, and the extension 122 of the retention structure 120 can include a short distance across 122S and a long distance across 122L, aligned with the short distance 120NS and long distance 120NL of the narrow portion 120N of the retention structure 120. The narrow portion 120 can include an indentation 120I sized to receive the sclera, and the indention 120I can include an indentation relative to a maximum dimension across the reservoir chamber 140 and the extension 122 such that the sclera is retained with the indentation 120I. The indentation 120I can include a portion of the extension 122, a portion of the shoulder 120S and a portion of the retention structure extending therebetween, for example.
The therapeutic device 100 can include a non-circular cross-sectional size, and the reservoir chamber 140 can include a rigid walled reservoir having a non-circular, for example elliptical or lentoid cross-sectional size.
FIG. 2C1 shows a side view of the short distance 120NS of the narrow portion 120N of the therapeutic device as in
FIG. 2C2 shows a side view of the long distance 120NL of the narrow portion 120N of the therapeutic device 100 as in
The penetrable barrier 184, for example the septum, can be inserted into the access port 180. The penetrable barrier can include an elastic material sized such that the penetrable barrier can be inserted into the access port 180. The implantable device can include penetrable barrier 184 having a first outer and a second inner surface and a thickness extending a distance 184D between the first surface and the second surface. The penetrable barrier can include one or more elastic materials such as siloxane or rubber. The penetrable barrier can include tabs 184T to retain the penetrable barrier in the access port. The penetrable barrier 184 can include a beveled upper rim 184R sized to seal the access port 180. The access port 180 of the reservoir container 130 can include a beveled upper surface to engage the beveled rim and seal the penetrable barrier against the access port 180 when the tabs 184T engage an inner annular or elongate channel of the access port. The penetrable barrier 184 can include an opaque material, for example a grey material, for example silicone, such that the penetrable barrier can be visualized by the patient and treating physician.
The reservoir container 130 of the device can include a rigid biocompatible material that extends at least from the retention structure to the rigid porous structure, such that the reservoir includes a substantially constant volume when the therapeutic agent is released with the rigid porous structure so as to maintain a stable release rate profile, for example when the patient moves. Alternatively or in combination, the reservoir container 130 can include an optically transmissive material such that the reservoir container 130 can be translucent, for example transparent, such that the chamber of reservoir 140 can be visualized when the device is loaded with therapeutic agent outside the patient prior to implantation, for example when injected with a formulation of therapeutic agent prior to implantation in the physician's office. This visualization of the reservoir 140 can be helpful to ensure that the reservoir 140 is properly filled with therapeutic agent by the treating physician or assistant prior to implantation. The reservoir container can include one or more of many biocompatible materials such as acrylates, polymethylmethacrylate, siloxanes, metals, titanium stainless steel, polycarbonate, polyetheretherketone (PEEK), polyethylene, polyethylene terephthalate (PET), polyimide, polyamide-imide, polypropylene, polysulfone, polyurethane, polyvinylidene fluoride or PTFE. The biocompatible material of the reservoir container can include an optically transmissive material such as one or more of acrylate, polyacrylate, methlymethacraylate, polymethlymethacrylate (PMMA), polyacarbonate or siloxane. The reservoir container 130 can be machined from a piece of material, or injection molded, so as to form the retention structure 120 including extension 122 and the elongate narrow portion 120NE. The extension 122 can include a translucent material such that the physician can visualize tissue under the flange to assess the patient and to decrease appearance of the device 100 when implanted. The reservoir container 130 can include a channel extending along axis 100A from the access port 180 to porous structure 150, such that formulation injected into device 100 can be released in accordance with the volume of the reservoir and release rate of the porous structure 150 as described herein. The porous structure 150 can be affixed to the distal end of therapeutic device 100, for example with glue. Alternatively or in combination, the distal end of the reservoir container 130 can include an inner diameter sized to receive the porous structure 150, and the reservoir container 130 can include a stop to position the porous structure 150 at a predetermined location on the distal end so as to define a predetermined size of reservoir 140.
The proximal handle 210 includes structures to manipulate the distal placement portion 220. The first extension 212 and second extension 214 may be combined in many ways to manipulate the distal placement portion 220. The first extension 212 and the second extension 214 may extend to opposing sides of the distal portion 220. The first extension 212 and the second extension 214 and can include a resilient spring having the extensions coupled together at the distal end portion 216, for example with a weld on the distal end portion 216. The user can urge the first extension 212 toward the second extension 214 against the resilient extensions as shown with arrows 218, and the user can release the extensions, such that the spring forces urges the first extension 212 away from the second extension 214 opposite arrows 218.
The distal placement portion 220 includes structures to hold and place the implantable device 100. The distal placement portion 220 includes a guide 230 and an engagement structure 250. The engagement structure 250 is configured to engage the implantable device 100, and the guide 230 is configured to facilitate alignment and access to the implantable device 100 with a needle or other filling device so as to place therapeutic agent inside the implantable device 100. The guide 230 can be located on a front 240 of the placement portion 220, and can be readily viewed by a user. The front 240 is located opposite a back 242. The guide 230 located on the front 240 allows viewing of the recess 231 when the needle is advanced into the recess, as will be described in more detail below. The distal placement portion 220 includes a first side 222 and a second side 224 located opposite the first side 222. The first side 222 is movable opposite the second side 224 so as to engage the implantable device 100 with the first side 222 and the second side 224.
The engagement structure 250 can be configured to contact the implantable device in many ways, and can include a first engagement structure 251 on first side 222 and a second engagement structure 253 on the second side 224 opposite the first engagement structure. The first engagement structure 251 on first side 222 includes a first projection 252 extending at least partially around axis 200A. The second engagement structure 252 on second side 224 includes a second projection 254 extending at least partially around axis 200A opposite the first projection 252. The first and second projections 252, 254 may extend circumferentially and axially in relation to axis 100.
The guide 230 of the distal placement portion 220 can be configured in many ways to guide a needle toward recess 231 when the insertion apparatus holds the implantable device with the engagement structure 250. The guide 230 can include the first side 222 and the second side 224. The guide 230 can include a plurality of recessed surfaces that allow a short needle to be used to place the therapeutic fluid including therapeutic agent 110 in the implantable device. The guide 230 can include a first proximal guide surface 232 and first intermediate guide surface 233, and a first distal guide surface 236 on the first side 222. The guide 230 can include a second proximal guide surface 234 and second intermediate guide surface 235, and a second distal guide surface 238 on the second side 224. The guide surfaces are arranged to provide a visual reference to a user advancing a needle and also provide a surface to support the needle connector and maintain alignment of the needle when placed.
The first extension 212 and the second extension 214 can be coupled to the distal placement portion 220 in many ways. The extensions can be coupled to the distal portion so that pressing the extensions together separates the first engagement structure 251 of the first side 222 from the second engagement structure 253 of the second side 224 as shown with arrows 228, for example (see
The first extension 212 and the second extension 214 can be affixed to the distal placement portion 220 in many ways. Fasteners 226 can be used to couple the extensions to the distal placement portion, for example.
The first extension 212 can be affixed to the second side 224 of the distal placement portion 220, and the second extension 214 can be affixed to the first side 222 of the distal placement portion 220.
The first protrusion 262 on first engagement structure 251 (
In many embodiments, the second engagement structure 253 includes structure similar to the first engagement structure 251 as described herein.
The first engagement structure 451 includes a first projection 452 and a second projection 456 which extend toward axis 400A, so as to define a channel 482 sized to receive the indentation 120N of the implantable device 100. The first projection 452 includes a tapered portion 462 extending to a leading edge 472. The second projection 456 includes a tapered portion 466 extending to a leading edge 476. The leading edges are configured to slide under the extension 122 of the retention structure 120.
The second engagement structure 453 includes a first projection 454 and a second projection 458 which extend toward axis 400A, so as to define a channel 484 sized to receive the indentation 120N of the implantable device 100. The first projection 454 includes a tapered portion 464 extending to a leading edge 474. The second projection 458 includes a tapered portion 468 extending to a leading edge 478. The leading edges are configured to slide under the extension 122 of the retention structure 120 opposite the leading edges of the engagement structure 451.
The axis 400A of the removal apparatus 400 can be aligned with the axis 100A of the implantable device 100 when the engagement structures are urged toward each other.
The retention structure 120 and the narrow portion 120N (
The removal tool 400 can be fabricated in many ways. For example, removal tool 400 can include a unitary structure. Alternatively, the extension and engagement structure of each side can include a unitary structure fabricated from a single piece of material, and the two unitary structures can be joined together at the proximal end 416 for example with a weld as described herein, for example.
While the exemplary embodiments have been described in some detail, by way of example and for clarity of understanding, those of skill in the art will recognize that a variety of modifications, adaptations, and changes may be employed. Hence, the scope of the present disclosure shall be limited solely by the appended claims.
This application is a continuation of co-pending U.S. application Ser. No. 14/376,331, filed as a national stage application, filed under 35 U.S.C. § 371, of PCT Application No. PCT/US2013/022770, filed on Jan. 23, 2013, which claims priority to U.S. Provisional Application No. 61/594,961 filed on Feb. 3, 2012, the contents of which are incorporated herein by reference in their entirety for all purposes.
Number | Name | Date | Kind |
---|---|---|---|
2564977 | Hu et al. | Aug 1951 | A |
2585815 | McLintock | Feb 1952 | A |
3232117 | Gilmont | Feb 1966 | A |
3416530 | Ness | Dec 1968 | A |
3618604 | Ness | Nov 1971 | A |
3641237 | Gould et al. | Feb 1972 | A |
3828777 | Ness | Aug 1974 | A |
3902495 | Weiss et al. | Sep 1975 | A |
3916899 | Theeuwes et al. | Nov 1975 | A |
3949748 | Malmin | Apr 1976 | A |
3949750 | Freeman | Apr 1976 | A |
3961628 | Arnold | Jun 1976 | A |
3977404 | Theeuwes | Aug 1976 | A |
3995635 | Higuchi et al. | Dec 1976 | A |
4008719 | Theeuwes et al. | Feb 1977 | A |
4014333 | McIntyre | Mar 1977 | A |
4014334 | Theeuwes et al. | Mar 1977 | A |
4014335 | Arnold | Mar 1977 | A |
4034756 | Higuchi et al. | Jul 1977 | A |
4034758 | Theeuwes | Jul 1977 | A |
4077407 | Theeuwes et al. | Mar 1978 | A |
4111201 | Theeuwes | Sep 1978 | A |
4111203 | Theeuwes | Sep 1978 | A |
4135514 | Zaffaroni et al. | Jan 1979 | A |
4160452 | Theeuwes | Jul 1979 | A |
4200098 | Ayer et al. | Apr 1980 | A |
4220152 | Dresback | Sep 1980 | A |
4220153 | Dresback | Sep 1980 | A |
4256108 | Theeuwes | Mar 1981 | A |
4298000 | Thill et al. | Nov 1981 | A |
4300557 | Refojo et al. | Nov 1981 | A |
4309776 | Berguer | Jan 1982 | A |
4326525 | Swanson et al. | Apr 1982 | A |
4327725 | Cortese et al. | May 1982 | A |
4439196 | Higuchi | Mar 1984 | A |
4475916 | Himmelstein | Oct 1984 | A |
4484922 | Rosenwald | Nov 1984 | A |
4519801 | Edgren | May 1985 | A |
4609374 | Ayer | Sep 1986 | A |
4627850 | Deters et al. | Dec 1986 | A |
4673405 | Guittard et al. | Jun 1987 | A |
4693886 | Ayer | Sep 1987 | A |
4712550 | Sinnett | Dec 1987 | A |
4737150 | Baeumle et al. | Apr 1988 | A |
4777049 | Magruder et al. | Oct 1988 | A |
4781675 | White | Nov 1988 | A |
4863457 | Lee | Sep 1989 | A |
4865846 | Kaufman | Sep 1989 | A |
4883459 | Calderon | Nov 1989 | A |
4959217 | Sanders et al. | Sep 1990 | A |
5084021 | Baldwin | Jan 1992 | A |
5098443 | Parel et al. | Mar 1992 | A |
5128145 | Edgren et al. | Jul 1992 | A |
5164188 | Wong | Nov 1992 | A |
5174999 | Magruder et al. | Dec 1992 | A |
5178622 | Lehner, II | Jan 1993 | A |
5277912 | Lowe et al. | Jan 1994 | A |
5282829 | Hermes | Feb 1994 | A |
5300114 | Gwon et al. | Apr 1994 | A |
5322691 | Darougar et al. | Jun 1994 | A |
5334189 | Wade | Aug 1994 | A |
5336175 | Mames | Aug 1994 | A |
5378475 | Smith et al. | Jan 1995 | A |
5413572 | Wong et al. | May 1995 | A |
5443505 | Wong et al. | Aug 1995 | A |
5476511 | Gwon et al. | Dec 1995 | A |
5516522 | Peyman et al. | May 1996 | A |
5554132 | Straits et al. | Sep 1996 | A |
5562915 | Lowe et al. | Oct 1996 | A |
5681572 | Seare, Jr. | Oct 1997 | A |
5702414 | Richter et al. | Dec 1997 | A |
5766242 | Wong et al. | Jun 1998 | A |
5770076 | Chu et al. | Jun 1998 | A |
5773019 | Ashton et al. | Jun 1998 | A |
5797898 | Santini, Jr. et al. | Aug 1998 | A |
5807581 | Rosenblatt et al. | Sep 1998 | A |
5824072 | Wong | Oct 1998 | A |
5830173 | Avery et al. | Nov 1998 | A |
5830546 | Ehret et al. | Nov 1998 | A |
5836935 | Ashton et al. | Nov 1998 | A |
5868697 | Richter et al. | Feb 1999 | A |
5902598 | Chen et al. | May 1999 | A |
5916584 | O'Donoghue et al. | Jun 1999 | A |
5928662 | Phillips | Jul 1999 | A |
5951512 | Dalton | Sep 1999 | A |
5972369 | Roorda et al. | Oct 1999 | A |
5985328 | Chu et al. | Nov 1999 | A |
6001386 | Ashton et al. | Dec 1999 | A |
6039712 | Fogarty | Mar 2000 | A |
6096070 | Ragheb et al. | Aug 2000 | A |
6123861 | Santini, Jr. et al. | Sep 2000 | A |
6196993 | Cohan et al. | Mar 2001 | B1 |
6303290 | Liu et al. | Oct 2001 | B1 |
6331313 | Wong et al. | Dec 2001 | B1 |
6375972 | Guo et al. | Apr 2002 | B1 |
6395300 | Straub et al. | May 2002 | B1 |
6413540 | Yaacobi | Jul 2002 | B1 |
6416777 | Yaacobi | Jul 2002 | B1 |
6420399 | Graff et al. | Jul 2002 | B1 |
6472162 | Coelho et al. | Oct 2002 | B1 |
6605066 | Gravagna et al. | Aug 2003 | B1 |
6663668 | Chaouk et al. | Dec 2003 | B1 |
6669950 | Yaacobi | Dec 2003 | B2 |
6685940 | Andya et al. | Feb 2004 | B2 |
6713081 | Robinson et al. | Mar 2004 | B2 |
6719750 | Varner et al. | Apr 2004 | B2 |
6740077 | Brandau et al. | May 2004 | B1 |
6756049 | Brubaker et al. | Jun 2004 | B2 |
6756058 | Brubaker et al. | Jun 2004 | B2 |
6932983 | Straub et al. | Aug 2005 | B1 |
6976982 | Santini, Jr. et al. | Dec 2005 | B2 |
6986900 | Yaacobi | Jan 2006 | B2 |
7026329 | Crain et al. | Apr 2006 | B2 |
7074426 | Kochinke | Jul 2006 | B2 |
7077848 | de Juan, Jr. et al. | Jul 2006 | B1 |
7090681 | Weber et al. | Aug 2006 | B2 |
7094226 | Yaacobi | Aug 2006 | B2 |
7117870 | Prescott | Oct 2006 | B2 |
7141152 | Le Febre | Nov 2006 | B2 |
7181287 | Greenberg | Feb 2007 | B2 |
7195774 | Carvalho et al. | Mar 2007 | B2 |
7195778 | Fleshner-Barak et al. | Mar 2007 | B2 |
7211272 | Renner et al. | May 2007 | B2 |
7252673 | Lim | Aug 2007 | B2 |
7276050 | Franklin | Oct 2007 | B2 |
7468065 | Weber et al. | Dec 2008 | B2 |
7476510 | Kapur et al. | Jan 2009 | B2 |
7585517 | Cooper et al. | Sep 2009 | B2 |
7615141 | Schwartz et al. | Nov 2009 | B2 |
7621907 | Rodstrom | Nov 2009 | B2 |
7625927 | Klimko et al. | Dec 2009 | B2 |
7678078 | Peyman et al. | Mar 2010 | B1 |
7686016 | Wharton et al. | Mar 2010 | B2 |
7709049 | Chappa | May 2010 | B2 |
7753916 | Weber et al. | Jul 2010 | B2 |
7883717 | Varner et al. | Feb 2011 | B2 |
7893040 | Loftsson et al. | Feb 2011 | B2 |
7906136 | Wong et al. | Mar 2011 | B2 |
7909800 | Cazzini | Mar 2011 | B2 |
7914442 | Gazdzinski | Mar 2011 | B1 |
7939094 | Schwarz et al. | May 2011 | B2 |
7973068 | Demopulos et al. | Jul 2011 | B2 |
8313454 | Yaron et al. | Nov 2012 | B2 |
8403941 | Peterson et al. | Mar 2013 | B2 |
9987163 | Schaller | Jun 2018 | B2 |
10010448 | de Juan, Jr. | Jul 2018 | B2 |
20020026176 | Varner et al. | Feb 2002 | A1 |
20020086051 | Viscasillas | Jul 2002 | A1 |
20020106395 | Brubaker | Aug 2002 | A1 |
20020110591 | Brubaker et al. | Aug 2002 | A1 |
20020110592 | Brubaker et al. | Aug 2002 | A1 |
20020110635 | Brubaker et al. | Aug 2002 | A1 |
20020116009 | Fraser et al. | Aug 2002 | A1 |
20020133168 | Smedley et al. | Sep 2002 | A1 |
20030003129 | Yaacobi | Jan 2003 | A1 |
20030005945 | Onishi et al. | Jan 2003 | A1 |
20030014036 | Varner et al. | Jan 2003 | A1 |
20030118649 | Gao et al. | Jun 2003 | A1 |
20030119177 | Gruber et al. | Jun 2003 | A1 |
20030176854 | Rodstrom | Sep 2003 | A1 |
20030185872 | Kochinke | Oct 2003 | A1 |
20030212383 | Cote et al. | Nov 2003 | A1 |
20030235603 | Schwarz et al. | Dec 2003 | A1 |
20040011651 | Becker et al. | Jan 2004 | A1 |
20040019325 | Shekalim | Jan 2004 | A1 |
20040092911 | Yaacobi | May 2004 | A1 |
20040106906 | Yaacobi | Jun 2004 | A1 |
20040131654 | Yaacobi | Jul 2004 | A1 |
20040131655 | Yaacobi | Jul 2004 | A1 |
20040209359 | Yayon et al. | Oct 2004 | A1 |
20040230183 | Breegi et al. | Nov 2004 | A1 |
20040238392 | Peterson et al. | Dec 2004 | A1 |
20040260380 | Marco et al. | Dec 2004 | A1 |
20040260381 | Marco et al. | Dec 2004 | A1 |
20050055031 | Lim | Mar 2005 | A1 |
20050064010 | Cooper et al. | Mar 2005 | A1 |
20050074497 | Schultz | Apr 2005 | A1 |
20050112175 | Yaacobi | May 2005 | A1 |
20050112759 | Radisic et al. | May 2005 | A1 |
20050113806 | De Carvalho et al. | May 2005 | A1 |
20050119737 | Bene et al. | Jun 2005 | A1 |
20050143363 | De Juan et al. | Jun 2005 | A1 |
20050154399 | Weber et al. | Jul 2005 | A1 |
20050163711 | Nycz et al. | Jul 2005 | A1 |
20050181018 | Peyman | Aug 2005 | A1 |
20050244467 | Nivaggioli et al. | Nov 2005 | A1 |
20050244469 | Whitcup et al. | Nov 2005 | A1 |
20050255144 | Schultz | Nov 2005 | A1 |
20050256499 | Pettis et al. | Nov 2005 | A1 |
20050271703 | Anderson et al. | Dec 2005 | A1 |
20050271706 | Anderson et al. | Dec 2005 | A1 |
20050276837 | Anderson et al. | Dec 2005 | A1 |
20050277802 | Larsen et al. | Dec 2005 | A1 |
20050281861 | Hughes et al. | Dec 2005 | A1 |
20050281863 | Anderson et al. | Dec 2005 | A1 |
20050287188 | Anderson et al. | Dec 2005 | A1 |
20060013835 | Anderson et al. | Jan 2006 | A1 |
20060039952 | Yaacobi | Feb 2006 | A1 |
20060052754 | Fields | Mar 2006 | A1 |
20060057277 | Chappa | Mar 2006 | A1 |
20060073182 | Wong et al. | Apr 2006 | A1 |
20060104969 | Oray et al. | May 2006 | A1 |
20060110428 | deJuan et al. | May 2006 | A1 |
20060129215 | Helmus et al. | Jun 2006 | A1 |
20060154981 | Klimko et al. | Jul 2006 | A1 |
20060172941 | Rastelli et al. | Aug 2006 | A1 |
20060182783 | Hughes et al. | Aug 2006 | A1 |
20060200097 | Humayun et al. | Sep 2006 | A1 |
20060233858 | Tzekov et al. | Oct 2006 | A1 |
20060246112 | Snyder et al. | Nov 2006 | A1 |
20060257450 | Mudumba et al. | Nov 2006 | A1 |
20060258000 | Allen et al. | Nov 2006 | A1 |
20060258994 | Avery | Nov 2006 | A1 |
20060276738 | Becker | Dec 2006 | A1 |
20070020336 | Loftsson et al. | Jan 2007 | A1 |
20070021357 | Tobia et al. | Jan 2007 | A1 |
20070026037 | Kloke et al. | Feb 2007 | A1 |
20070059336 | Hughes et al. | Mar 2007 | A1 |
20070071756 | Peyman | Mar 2007 | A1 |
20070072933 | Peyman | Mar 2007 | A1 |
20070077270 | Wen | Apr 2007 | A1 |
20070088414 | Campbell et al. | Apr 2007 | A1 |
20070119450 | Wharton et al. | May 2007 | A1 |
20070128644 | Munenaka | Jun 2007 | A1 |
20070131610 | Peng et al. | Jun 2007 | A1 |
20070131611 | Peng et al. | Jun 2007 | A1 |
20070134305 | Zilberman | Jun 2007 | A1 |
20070141111 | Suokas et al. | Jun 2007 | A1 |
20070191863 | De Juan et al. | Aug 2007 | A1 |
20070197491 | Robin et al. | Aug 2007 | A1 |
20070203174 | Klimko et al. | Aug 2007 | A1 |
20070212397 | Roth | Sep 2007 | A1 |
20070233037 | Gifford et al. | Oct 2007 | A1 |
20070235331 | Simpson et al. | Oct 2007 | A1 |
20070243230 | de Juan et al. | Oct 2007 | A1 |
20070260201 | Prausnitz et al. | Nov 2007 | A1 |
20070269487 | de Juan et al. | Nov 2007 | A1 |
20080003219 | Peyman | Jan 2008 | A1 |
20080004329 | Jamieson et al. | Jan 2008 | A1 |
20080020045 | Chappa et al. | Jan 2008 | A1 |
20080038316 | Wong et al. | Feb 2008 | A1 |
20080057561 | Takahashi et al. | Mar 2008 | A1 |
20080066739 | LeMahieu et al. | Mar 2008 | A1 |
20080066741 | LeMahieu et al. | Mar 2008 | A1 |
20080069854 | Xiao et al. | Mar 2008 | A1 |
20080089923 | Burkstrand et al. | Apr 2008 | A1 |
20080097459 | Kammerlander et al. | Apr 2008 | A1 |
20080111282 | Xie et al. | May 2008 | A1 |
20080124372 | Hossainy et al. | May 2008 | A1 |
20080139674 | Archambeau et al. | Jun 2008 | A1 |
20080145406 | Asgharian et al. | Jun 2008 | A1 |
20080146679 | Archambeau et al. | Jun 2008 | A1 |
20080147021 | Jani | Jun 2008 | A1 |
20080152694 | Lobl et al. | Jun 2008 | A1 |
20080154241 | Burkstrand et al. | Jun 2008 | A1 |
20080161741 | Bene et al. | Jul 2008 | A1 |
20080167600 | Peyman | Jul 2008 | A1 |
20080172014 | Whitcup et al. | Jul 2008 | A1 |
20080181930 | Rodstrom et al. | Jul 2008 | A1 |
20080200922 | Brown | Aug 2008 | A1 |
20080207502 | Rastelli et al. | Aug 2008 | A1 |
20080213611 | Asgari | Sep 2008 | A1 |
20080216736 | David | Sep 2008 | A1 |
20080228127 | Burns et al. | Sep 2008 | A1 |
20080233053 | Gross et al. | Sep 2008 | A1 |
20080233171 | Whitcup et al. | Sep 2008 | A1 |
20080233172 | Whitcup et al. | Sep 2008 | A1 |
20080233173 | Whitcup et al. | Sep 2008 | A1 |
20080241219 | Whitcup et al. | Oct 2008 | A1 |
20080241220 | Whitcup et al. | Oct 2008 | A1 |
20080241221 | Whitcup et al. | Oct 2008 | A1 |
20080241222 | Whitcup et al. | Oct 2008 | A1 |
20080241223 | Nivaggioli et al. | Oct 2008 | A1 |
20080249501 | Yamasaki | Oct 2008 | A1 |
20080286338 | Rosenthal et al. | Nov 2008 | A1 |
20080292679 | Lyons et al. | Nov 2008 | A1 |
20090005864 | Eggleston | Jan 2009 | A1 |
20090036827 | Cazzini | Feb 2009 | A1 |
20090043253 | Podaima | Feb 2009 | A1 |
20090047335 | Rastelli et al. | Feb 2009 | A1 |
20090082631 | Cronin et al. | Mar 2009 | A1 |
20090087494 | Kompella et al. | Apr 2009 | A1 |
20090092654 | de Juan, Jr. et al. | Apr 2009 | A1 |
20090093752 | Richard et al. | Apr 2009 | A1 |
20090099626 | de Juan, Jr. et al. | Apr 2009 | A1 |
20090104243 | Utkhede et al. | Apr 2009 | A1 |
20090105749 | de Juan et al. | Apr 2009 | A1 |
20090124997 | Pettis et al. | May 2009 | A1 |
20090214601 | Chappa et al. | Aug 2009 | A1 |
20090224064 | Brodbeck et al. | Sep 2009 | A1 |
20090234449 | De Juan, Jr. et al. | Sep 2009 | A1 |
20090240215 | Humayun et al. | Sep 2009 | A1 |
20090247458 | Watson et al. | Oct 2009 | A1 |
20090258069 | Burnier et al. | Oct 2009 | A1 |
20090263346 | Taft et al. | Oct 2009 | A1 |
20090263495 | Watson et al. | Oct 2009 | A1 |
20090274730 | Watson et al. | Nov 2009 | A1 |
20090274771 | Watson et al. | Nov 2009 | A1 |
20090280470 | Fare et al. | Nov 2009 | A1 |
20090281621 | Becker | Nov 2009 | A1 |
20090324686 | Cooper et al. | Dec 2009 | A1 |
20090324687 | Cooper et al. | Dec 2009 | A1 |
20090324688 | Cooper et al. | Dec 2009 | A1 |
20090324689 | Cooper et al. | Dec 2009 | A1 |
20090324690 | Cooper et al. | Dec 2009 | A1 |
20090326448 | Huo et al. | Dec 2009 | A1 |
20100003333 | Watson et al. | Jan 2010 | A1 |
20100004189 | Watson et al. | Jan 2010 | A1 |
20100008997 | Watson et al. | Jan 2010 | A1 |
20100009008 | Watson et al. | Jan 2010 | A1 |
20100010452 | Paques et al. | Jan 2010 | A1 |
20100011888 | Pawliszyn et al. | Jan 2010 | A1 |
20100015157 | Andya et al. | Jan 2010 | A1 |
20100016786 | Drews et al. | Jan 2010 | A1 |
20100021464 | Archambeau et al. | Jan 2010 | A1 |
20100022943 | Mauch et al. | Jan 2010 | A1 |
20100022945 | Rodstrom | Jan 2010 | A1 |
20100023033 | Mauch et al. | Jan 2010 | A1 |
20100028442 | Archambeau et al. | Feb 2010 | A1 |
20100028443 | Watson et al. | Feb 2010 | A1 |
20100030136 | Dacquay et al. | Feb 2010 | A1 |
20100034870 | Sim et al. | Feb 2010 | A1 |
20100083963 | Wharton et al. | Apr 2010 | A1 |
20100100054 | Cormier et al. | Apr 2010 | A1 |
20100100104 | Yu et al. | Apr 2010 | A1 |
20100114017 | Lenker et al. | May 2010 | A1 |
20100114309 | de Juan, Jr. et al. | May 2010 | A1 |
20100168535 | Robinson et al. | Jul 2010 | A1 |
20100174272 | Weiner | Jul 2010 | A1 |
20100185205 | Novakovic et al. | Jul 2010 | A1 |
20100197512 | Trinkle et al. | Aug 2010 | A1 |
20100216702 | Szkudlinski et al. | Aug 2010 | A1 |
20100221309 | Myers et al. | Sep 2010 | A1 |
20100241102 | Ma | Sep 2010 | A1 |
20100255061 | de Juan, Jr. et al. | Oct 2010 | A1 |
20100256597 | Prausnitz et al. | Oct 2010 | A1 |
20100266664 | Asgharian et al. | Oct 2010 | A1 |
20100286121 | Rohrs et al. | Nov 2010 | A1 |
20100286791 | Goldsmith | Nov 2010 | A1 |
20100297046 | Schwartz et al. | Nov 2010 | A1 |
20100297120 | Beliveau et al. | Nov 2010 | A1 |
20100297193 | Archambeau et al. | Nov 2010 | A1 |
20100303917 | Watson et al. | Dec 2010 | A1 |
20100303918 | Watson et al. | Dec 2010 | A1 |
20100310664 | Watson et al. | Dec 2010 | A1 |
20100310665 | Watson et al. | Dec 2010 | A1 |
20100316723 | Watson et al. | Dec 2010 | A1 |
20100330146 | Chauhan et al. | Dec 2010 | A1 |
20110009571 | Taft et al. | Jan 2011 | A1 |
20110014264 | Helmus et al. | Jan 2011 | A1 |
20110033933 | Gharib et al. | Feb 2011 | A1 |
20110034448 | Chang et al. | Feb 2011 | A1 |
20110081384 | Archambeau et al. | Apr 2011 | A1 |
20110098686 | Varner et al. | Apr 2011 | A1 |
20110104155 | Rekik | May 2011 | A1 |
20110108025 | Fink et al. | May 2011 | A1 |
20110111006 | Wong et al. | May 2011 | A1 |
20110112188 | Tobia et al. | May 2011 | A1 |
20110117083 | Bais et al. | May 2011 | A1 |
20110125178 | Drews et al. | May 2011 | A1 |
20110159073 | deJuan et al. | Jun 2011 | A1 |
20110196317 | Lust | Aug 2011 | A1 |
20110206646 | Alfonso et al. | Aug 2011 | A1 |
20120029445 | de Juan, Jr. et al. | Feb 2012 | A1 |
20120029470 | Juan, Jr. et al. | Feb 2012 | A1 |
20120245505 | Robinson et al. | Sep 2012 | A1 |
20130218081 | Roth | Aug 2013 | A1 |
20130274691 | de Juan, Jr. et al. | Oct 2013 | A1 |
20130274692 | Alster et al. | Oct 2013 | A1 |
20140031769 | de Juan, Jr. et al. | Jan 2014 | A1 |
20140073714 | Reich et al. | Mar 2014 | A1 |
20140114323 | Kudo et al. | Apr 2014 | A1 |
20140221941 | Erickson et al. | Aug 2014 | A1 |
20140276901 | Auld | Sep 2014 | A1 |
20140303637 | Downer et al. | Oct 2014 | A1 |
20140326249 | Cappiello et al. | Nov 2014 | A1 |
20140358125 | de Juan, Jr. et al. | Dec 2014 | A1 |
20140379079 | Ben Nun | Dec 2014 | A1 |
20150045805 | Kontur et al. | Feb 2015 | A1 |
20150297402 | de Juan, Jr. et al. | Oct 2015 | A1 |
20160101046 | Reich et al. | Apr 2016 | A1 |
20160184134 | Varner et al. | Jun 2016 | A1 |
20160258855 | Farinas et al. | Sep 2016 | A1 |
20160302965 | Erickson et al. | Oct 2016 | A1 |
20170165108 | Bianchi et al. | Jun 2017 | A1 |
20170165110 | Erickson et al. | Jun 2017 | A1 |
20170172794 | Varner et al. | Jun 2017 | A1 |
20170258634 | de Juan, Jr. et al. | Sep 2017 | A1 |
20180161202 | de Juan, Jr. et al. | Jun 2018 | A1 |
20180243130 | Doud et al. | Aug 2018 | A1 |
20180243131 | Erickson et al. | Aug 2018 | A1 |
20180292403 | de Juan, Jr. et al. | Oct 2018 | A1 |
Number | Date | Country |
---|---|---|
102098993 | Jun 2011 | CN |
0 228 185 | Nov 1986 | EP |
0498471 | Aug 1992 | EP |
0500143 | Aug 1992 | EP |
0671165 | Sep 1995 | EP |
0295248 | Apr 1999 | EP |
0944658 | Jun 2003 | EP |
1671624 | Jun 2006 | EP |
1385452 | Sep 2006 | EP |
1409065 | Jan 2007 | EP |
1337284 | Dec 2007 | EP |
1911481 | Apr 2008 | EP |
1521572 | Mar 2009 | EP |
2004525695 | Aug 2004 | JP |
2387462 | Apr 2010 | RU |
WO-8804573 | Jun 1988 | WO |
WO-9007545 | Jul 1990 | WO |
WO-9528984 | Nov 1995 | WO |
WO-9729850 | Aug 1997 | WO |
WO-9825982 | Jun 1998 | WO |
WO-0048660 | Aug 2000 | WO |
WO-0126714 | Apr 2001 | WO |
WO-0150943 | Jul 2001 | WO |
WO-03077972 | Sep 2003 | WO |
WO-03082188 | Oct 2003 | WO |
WO-2004000267 | Dec 2003 | WO |
WO-2004112653 | Dec 2004 | WO |
WO 2005016401 | Feb 2005 | WO |
WO-2005027906 | Mar 2005 | WO |
WO-2005028006 | Mar 2005 | WO |
WO-2005091922 | Oct 2005 | WO |
WO-2005107705 | Nov 2005 | WO |
WO-2005110362 | Nov 2005 | WO |
WO-2005110436 | Nov 2005 | WO |
WO-2005110473 | Nov 2005 | WO |
WO-2005117780 | Dec 2005 | WO |
WO-2006014484 | Feb 2006 | WO |
WO-2006015385 | Feb 2006 | WO |
WO-2006023530 | Mar 2006 | WO |
WO-2006031358 | Mar 2006 | WO |
WO-2006031388 | Mar 2006 | WO |
WO-2006044614 | Apr 2006 | WO |
WO-2006068838 | Jun 2006 | WO |
WO-2006071554 | Jul 2006 | WO |
WO-2006082588 | Aug 2006 | WO |
WO-2006108054 | Oct 2006 | WO |
WO-2006125106 | Nov 2006 | WO |
WO-2006127962 | Nov 2006 | WO |
WO-2006138609 | Dec 2006 | WO |
WO-2007012974 | Feb 2007 | WO |
WO-2007035621 | Mar 2007 | WO |
WO-2007038453 | Apr 2007 | WO |
WO-2007044534 | Apr 2007 | WO |
WO-2007047744 | Apr 2007 | WO |
WO 2007066339 | Jun 2007 | WO |
WO 2007084582 | Jul 2007 | WO |
WO-2007084765 | Jul 2007 | WO |
WO-2007101204 | Sep 2007 | WO |
WO-2007117394 | Oct 2007 | WO |
WO-2007131050 | Nov 2007 | WO |
WO-2007133761 | Nov 2007 | WO |
WO-2007133762 | Nov 2007 | WO |
WO-2008003043 | Jan 2008 | WO |
WO-2008005240 | Jan 2008 | WO |
WO-2008011125 | Jan 2008 | WO |
WO-2008033924 | Mar 2008 | WO |
WO-2008040062 | Apr 2008 | WO |
WO-2008045272 | Apr 2008 | WO |
WO-2008052145 | May 2008 | WO |
WO-2008060359 | May 2008 | WO |
WO-2008061043 | May 2008 | WO |
WO-2008076544 | Jun 2008 | WO |
WO-2008094989 | Aug 2008 | WO |
WO-2008115290 | Sep 2008 | WO |
WO-2008116165 | Sep 2008 | WO |
WO-2008144340 | Nov 2008 | WO |
WO-2008144919 | Dec 2008 | WO |
WO-2009012075 | Jan 2009 | WO |
WO-2009023615 | Feb 2009 | WO |
WO-2009046164 | Apr 2009 | WO |
WO-2009055620 | Apr 2009 | WO |
WO-2009055671 | Apr 2009 | WO |
WO-2009055729 | Apr 2009 | WO |
WO-2009055824 | Apr 2009 | WO |
WO-2009061607 | May 2009 | WO |
WO-2009073192 | Jun 2009 | WO |
WO-2009086112 | Jul 2009 | WO |
WO-2009089409 | Jul 2009 | WO |
WO-2009094466 | Jul 2009 | WO |
WO-2009112878 | Sep 2009 | WO |
WO-2009117112 | Sep 2009 | WO |
WO-2009124096 | Oct 2009 | WO |
WO-2009128932 | Oct 2009 | WO |
WO-2009134929 | Nov 2009 | WO |
WO-2009137777 | Nov 2009 | WO |
WO-2010008424 | Jan 2010 | WO |
WO-2010021993 | Feb 2010 | WO |
WO-2010047753 | Apr 2010 | WO |
WO-2010062628 | Jun 2010 | WO |
WO-2010066714 | Jun 2010 | WO |
WO-2010075565 | Jul 2010 | WO |
WO-2010078063 | Jul 2010 | WO |
WO-2010080987 | Jul 2010 | WO |
WO-2010088548 | Aug 2010 | WO |
WO-2010093945 | Aug 2010 | WO |
WO-2010095940 | Aug 2010 | WO |
WO-2010125416 | Nov 2010 | WO |
WO-2010126908 | Nov 2010 | WO |
WO-2010135369 | Nov 2010 | WO |
WO-2010141729 | Dec 2010 | WO |
WO-2010147661 | Dec 2010 | WO |
WO-2011008896 | Jan 2011 | WO |
WO-2011008897 | Jan 2011 | WO |
WO-2011028850 | Mar 2011 | WO |
WO-2011034627 | Mar 2011 | WO |
WO-2011079232 | Jun 2011 | WO |
WO-2012019136 | Feb 2012 | WO |
WO-2013082452 | Jun 2013 | WO |
WO-2013116061 | Aug 2013 | WO |
Entry |
---|
Andrews, “Effect of nonsteroidal anti-inflammatory drugs on LFA-1 and ICAM-1 expression in gastric mucosa,” Am J Physiol. Apr. 1994; 266(4 Pt 1):G657-664. |
Avery et al., “Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy,” Ophthalmology. Oct. 2006, 113(10):1695-1705.e6. |
Bakri et al., “The effect of intravitreal triamcinolone acetonide on intraocular pressure,” Ophthalmic Surgery, Lasers and Imaging, Sep./Oct. 2003; 34(5): 386-390. |
Bird et al., Transport Phenomena, John Wiley & Sons, Inc., New York, 1960, pp. 196-201. |
Block et al., “Solubility and dissolution of triamcinolone acetonide,” Journal of Pharmaceutical Sciences, Apr. 1973; 62(4):617-621. |
Castro et al., “Effect of COX inhibitors on VEGF-induced retinal vascular leakage and experimental corneal and choroidal neovascularization,” Exp Eye Res. Aug. 2004;79(2):275-285. |
Chirila et al., “The Vitreous Humor” in Handbook of Biomaterial Properties, eds. Black & Hastings. Chapman & Hall, London, 1998; pp. 125-131. |
Cousins et al., “Program # 1251—Targeting Complement Factor 5 in Combination with Vascular Endothelial Growth Factor (VEGF) Inhibition for Neovascular Age Related Macular Degeneration (AMD): Results of a Phase 1 Study,” [Presentation Abstract], AMD Clinical Trials Session # 220, May 3, 2010. 2 pages. |
Deissler et al., “VEGF-induced effects on proliferation, migration and tight junctions are restored by ranibizumab (Lucentis) in microvascular retinal endothelial cells.” Br J Ophthalmol 2008;92:839-843. |
Donoso et al., “The role of inflammation in the pathogenesis of age-related macular degeneration,” Surv Ophthalmol. Mar.-Apr. 2006;51(2):137-52. |
Edelhauser, H et al. “Ophthalmic Drug Delivery Systems for the Treatment of Retinal Diseases Basic Research to Clinical Applications.” Investigative Ophthalmology & Visual Science, Nov. 2010. vol. 51, No. 11. pp. 5403-5420. |
European Medicine Agency, Scientific Discussion; retrieved from the Internet; <http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000715/VVC500043550.pdf>, EMEA 2007, 54 pages total. 2007. |
Funatsu et al. “Association of vitreous inflammatory factors with diabetic macular edema,” Ophthalmology 2009;116:73-79. |
Gaudreault et al., “Preclinical Pharmacokinetics of Ranibizumab (rhuFabV2) after a Single Intravitreal Administration,” Investigative Ophthalmology and Visual Science. 2005;46:726-733. Retrieved from the Internet: <<http://www.iovs.org/cgi/reprint/46/2/726>>. |
Gillies et al., “Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial,” Ophthalmology. Sep. 2006;113(9):1533-1538. |
Hastedt & Wright, “Diffusion in porous materials above the percolation threshold,” Pharm. Res. Sep. 1990; 7(9):893-901 (1990). |
Heier et al, “Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema,” Ophthalmology. Nov. 2000;107(11):2034-2038; discussion 2039. |
International Search Report dated Jun. 18, 2013, for PCT application No. PCT/US2013/022770. |
Jena et al., “A Novel Technique for Surface Area and Particle Size Determination of Components of Fuel Cells and Batteries,” Porous Materials, Inc., Dec. 2006, 3 pages total. Downloaded from the Internet: <<http://www.pmiapp.com/publications/docs/A_Novel_technique_for_surface_area.pdf>>. |
Kang et al., “Inhibitory effects of anti-inflammatory drugs on interleukin-6 bioactivity,” Biol Pharm Bull. Jun. 2001;24(6):701-703. |
Lopez-Armada et al., “Modulation of cell recruitment by anti-inflammatory agents in antigen-induced arthritis,” Ann Rheum Dis Nov. 2002;61(11):1027-1030. |
Luncentis, INN-Ranibizumab, “Scientific Discussion,” European Medicines Agency; retrieved from the Internet:<http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_- _ Assessment_Report_-_Variation/human/000715/WC500101009.pdf>. Oct. 21, 2010, 32 pages. |
Metal Powder Industries Federation, Porous Metal Design Guidebook, 2007, 24 pages total. Downloaded from the Internet: <<http://www.mpif.org/DesignCenter/porous.pdf>>. |
Mott Corporation, “Sintered Metal Powder Media,” American Filtration & Separation Society 2007, 2 pages total. Downloaded from the Internet:<<http://www.afssociety.org/education/0907oneminute.htm>>. |
Navarro, “The Optical Design of the Human Eye: a Critical Review,” J Optom, Jan.-Mar. 2009 2(1): 3-18. |
Okabe et al., “Intraocular tissue distribution of betamethasone after intrascleral administration using a non-biodegradable sustained drug delivery device,” Investigative Ophthalmology and Visual Science. 2003;44:2702-2707. Downloaded from the Internet: <<http://www.iovs.org/cgi/reprint/44/6/2702>>. |
Rosenfeld, “The Latest Research: Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy,” Review of Ophthalmology's Retina Online, Feb. 2006 2 pages. retrieved from the Internet: http://www.revophth.com/archive/newsletter/0206_retina.htm. |
Smith et al., “Spectrophotometric determination of pKa values for fluorescein using activity coefficient corrections,” WaterSA 2002; 28(4):395-402. |
Soheilian et al., “Pilot Study of Intravitreal Injection of Diclofenac for Treatment of Macular Edema of Various Etiologies,” Retina, Mar. 2010; 30(3): 509-515. |
Theodossiadis et al., “Intravitreal administration of the anti-tumor necrosis factor agent infliximab for neovascular age-related macular degeneration,” Am J Ophthalmol. May 2009;147(5):825-830. |
Williams et al., “Treating Diabetic Macular Edema With Ocular NSAIDs,” Retinal Physician, Nov. 2007; retrieved from the Internet Nov. 11, 2007. http://www.retinalphysician.com/article.aspx?article=101096>, 5 pages total. |
Number | Date | Country | |
---|---|---|---|
20180289542 A1 | Oct 2018 | US |
Number | Date | Country | |
---|---|---|---|
61594961 | Feb 2012 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14376331 | US | |
Child | 16004085 | US |